{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-26-000028","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.257088+00:00","generated_at":"2026-05-16T00:25:25.208733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GoodRx reports Q4 revenue $194.8M, Adj. EBITDA $65.0M; Pharma Direct grows >40% YoY for 2025","bullets":["Q4 2025 revenue $194.8M, net income $5.4M, Adjusted EBITDA $65.0M (33.4% margin).","Full-year 2025 revenue $796.9M, net income $30.4M, Adjusted EBITDA $270.5M (33.9% margin).","Pharma Direct revenue beat prior outlook with over 40% year-over-year growth in 2025.","CEO Wendy Barnes notes strong finish, rebranded Pharma Manufacturer Solutions as Pharma Direct.","Adjusted Net Income Q4 $29.0M (14.9% margin); FY $126.1M (15.8% margin)."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-26-000028","json":"https://secwatch.observer/filing/0001809519-26-000028.json","markdown":"https://secwatch.observer/filing/0001809519-26-000028.md","text":"https://secwatch.observer/filing/0001809519-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000028/0001809519-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000028/gdrx-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:25:25.208733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}